PPARα agonist 5

PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM) . PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM) . PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia[1].

Product Specifications

UNSPSC

12352005

Target

Phosphatase; PPAR

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Metabolic Disease; Cardiovascular Disease

Smiles

O=C(O)[C@@](C1=CC=CC=C1)(C)OC(C=C2)=CC=C2C3=C(C=CC=C4)C4=CC=C3

Molecular Formula

C25H20O3

Molecular Weight

368.42

References & Citations

[1]Laghezza A, et al. A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model. Eur J Med Chem. 2025 May 5;289:117494.